Do you want to read an article? Please log in or register.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Genitourinary Cancer
Related content
ESMO 2025
Genitourinary Cancer
EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer
Genitourinary Cancer
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Eur J Cancer
Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ
doi: 10.1016/j.ejca.2025.116110
COMMENTED
Genitourinary Cancer
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004890
Genitourinary Cancer
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints
J Urol
Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EP, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004879
Genitourinary Cancer
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany
Prostate Cancer Prostatic Dis
Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, Kraywinkel K, Thomas C, Boehm K
doi: 10.1038/s41391-026-01092-w
Genitourinary Cancer
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K
doi: 10.1016/S0140-6736(25)00684-1
Genitourinary Cancer
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer
Adv Ther
Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND
doi: 10.1007/s12325-025-03207-6
Genitourinary Cancer
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N
doi: 10.1016/S0140-6736(25)00683-X
Genitourinary Cancer
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
Eur Urol
Ghadjar P, Hayoz S, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Hoffmann E, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Riesterer O, Beck M, Thalmann GN, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.eururo.2025.12.020